Company intelligence / Profile preview

OVB

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

OVB (Oncolytic Virus Bio) is a South Korean biotechnology company specializing in the development of next-generation oncolytic virus therapies for the treatment of various solid tumors. The company leverages a proprietary platform to engineer viruses that selectively infect and lyse cancer cells while simultaneously stimulating a systemic anti-tumor immune response. Their pipeline focuses on high-unmet-need indications such as glioblastoma and pancreatic cancer, utilizing advanced genetic modification techniques to enhance viral potency and safety. OVB aims to overcome the limitations of current immunotherapies by transforming the tumor microenvironment from "cold" to "hot."

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyBiologicGene therapy
Industry: Biotech

Beyond the preview

Go deeper on OVB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVB.

Explore the full profile